SG10201809363SA - Methods of treatment of ocular conditions with a sustained drug delivery implant - Google Patents

Methods of treatment of ocular conditions with a sustained drug delivery implant

Info

Publication number
SG10201809363SA
SG10201809363SA SG10201809363SA SG10201809363SA SG10201809363SA SG 10201809363S A SG10201809363S A SG 10201809363SA SG 10201809363S A SG10201809363S A SG 10201809363SA SG 10201809363S A SG10201809363S A SG 10201809363SA SG 10201809363S A SG10201809363S A SG 10201809363SA
Authority
SG
Singapore
Prior art keywords
corticosteroid
ocular conditions
treatment
methods
drug delivery
Prior art date
Application number
SG10201809363SA
Inventor
Jane-Guo Shiah
Rahul Bhagat
Wendy M Blanda
Thierry Nivaggioli
Lin Peng
David Chou
David A Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201809363S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of SG10201809363SA publication Critical patent/SG10201809363SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

METHODS OF TREATMENT OF OCULAR CONDITIONS WITH A SUSTAINED DRUG DELIVERY IMPLANT Intraocular implants may include a corticosteroid and a biodegradable polymer associated with the corticosteroid to facilitate the release of the corticosteroid into an eye for a period of time. In some embodiments, ocular conditions, such as diabetic macular edema can be treated through administration of an intraocular implant including a corticosteroid and a biodegradable polymer associated with the corticosteroid to the eye of a human at a frequency of about once every six months to about once a year. Fig. 7
SG10201809363SA 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant SG10201809363SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15

Publications (1)

Publication Number Publication Date
SG10201809363SA true SG10201809363SA (en) 2018-11-29

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201809363SA SG10201809363SA (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Country Status (24)

Country Link
US (1) US20150140062A1 (en)
EP (2) EP3714875A1 (en)
JP (2) JP6675307B2 (en)
KR (2) KR20220082934A (en)
CN (1) CN105764517A (en)
AU (3) AU2014348369B2 (en)
CA (1) CA2929689A1 (en)
CL (1) CL2016001167A1 (en)
CY (1) CY1123344T1 (en)
DK (1) DK3068403T3 (en)
ES (1) ES2819215T3 (en)
HU (1) HUE050913T2 (en)
IL (2) IL245548A0 (en)
MX (2) MX2016006334A (en)
MY (1) MY176039A (en)
NZ (1) NZ719953A (en)
PH (1) PH12016500869A1 (en)
PL (1) PL3068403T3 (en)
PT (1) PT3068403T (en)
RU (1) RU2690841C1 (en)
SG (1) SG10201809363SA (en)
SI (1) SI3068403T1 (en)
UA (1) UA122117C2 (en)
WO (1) WO2015073895A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337254A (en) * 2015-07-23 2022-11-15 爱瑞制药公司 Intravitreal drug delivery system for treating ocular diseases
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11690806B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
ES2250504T3 (en) 2000-11-29 2006-04-16 Allergan Inc. PREVENTION OF REJECTION OF GRAFT IN THE EYE.
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
WO2012109673A1 (en) * 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Also Published As

Publication number Publication date
IL290837A (en) 2022-04-01
MX2022002306A (en) 2022-03-25
AU2014348369A1 (en) 2016-06-09
PH12016500869B1 (en) 2016-07-04
MY176039A (en) 2020-07-22
RU2690841C1 (en) 2019-06-06
DK3068403T3 (en) 2020-09-07
JP6675307B2 (en) 2020-04-01
AU2022204607A1 (en) 2022-07-21
JP7022735B2 (en) 2022-02-18
EP3068403B1 (en) 2020-06-17
AU2020204362A1 (en) 2020-07-23
CA2929689A1 (en) 2015-05-21
RU2016119132A (en) 2017-12-20
JP2020055862A (en) 2020-04-09
EP3068403A1 (en) 2016-09-21
JP2016538292A (en) 2016-12-08
CN105764517A (en) 2016-07-13
SI3068403T1 (en) 2020-11-30
US20150140062A1 (en) 2015-05-21
HUE050913T2 (en) 2021-01-28
PT3068403T (en) 2020-09-18
CL2016001167A1 (en) 2017-01-06
PL3068403T3 (en) 2021-01-11
EP3714875A1 (en) 2020-09-30
WO2015073895A1 (en) 2015-05-21
AU2014348369B2 (en) 2020-04-02
CY1123344T1 (en) 2021-12-31
PH12016500869A1 (en) 2016-07-04
KR20220082934A (en) 2022-06-17
NZ719953A (en) 2022-01-28
UA122117C2 (en) 2020-09-25
MX2016006334A (en) 2016-09-06
ES2819215T3 (en) 2021-04-15
KR102475746B1 (en) 2022-12-08
KR20160085847A (en) 2016-07-18
IL245548A0 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2018014763A (en) Intraocular drug delivery.
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
WO2011084366A3 (en) Compositions and drug delivery systems for intraocular delivery of sirna molecules, their use for treating conditions
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
EA201590902A1 (en) METHODS AND DEVICES APPLICABLE FOR THE TREATMENT OF EYE DISEASES IN HUMAN
MX2016011173A (en) Intraocular implant delivery apparatus and methods of use thereof.
EA201491711A1 (en) CONJUGATES OF NONLINEAR MULTIPLACE COPOLYMER WITH A MEDICINE FOR DELIVERY OF ACTIVE AGENTS
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
TN2016000162A1 (en) Eye device.
WO2013148275A9 (en) System for delivering multiple ocular implants
MX2018014868A (en) Compositions and methods of using nintedanib for improving glaucoma surgery success.
CY1123344T1 (en) METHODS OF TREATMENT OF OTHLIC CONDITIONS WITH A SUSTAINED DRUG-RELEASE IMPLANT
BR112015006929A2 (en) biodegradable drug delivery systems for sustained protein release
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
WO2014143754A3 (en) Prostamide-containing intraocular implant
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
IN2014DN09713A (en)
MD722Z (en) Device and method for treating senile cataract
TH1601002766A (en) Methods for treating eye ailments with gradual drug delivery implants
RU2015154876A (en) METHOD FOR SURGICAL TREATMENT OF DIABETIC MACULAR Edema WITH VITREOMACULAR TRACTION
Webb FDA approves telescope implant.
UA45997U (en) "masoud iol capsule" ophthalmologic device
Xiao Macular oedema and retinal detachment: 2 case reports
Brodell Subcutaneous lipoatrophy treated with polylactic acid: case report
RU2009107387A (en) METHOD FOR TREATING CATARACTS OF PATIENTS WITH DYSTROPHIC DISEASES OF THE RETAIL